Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 5, 1997, Pages 433-438

  Hoki, Yuko ^a,c   Fujimori, Akira ^a,c   Pommier, Yves ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Camptothecin; Cancer chemotherapy; Multidrug resistance; P glycoprotein(MDR); Topoisomerase I

Indexed keywords

10,11 METHYLENEDIOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE; GLYCOPROTEIN P; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL LINE; CELL STRAIN 3T3; CELL STRAIN KB; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, NORTHERN; BLOTTING, WESTERN; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KB CELLS; P-GLYCOPROTEIN; TIME FACTORS; TOPOTECAN; UP-REGULATION;

EID: 0030738095     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050682     Document Type: Article

References (48)

1. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufmann SH (1993) The current status of camptothecin analogs as anticancer agents. J Natl Cancer Inst 85: 271
2. Potmesil M (1994) Camptothecins: from bench research to hospital wards. Cancer Res 54: 1431
3. Slichenmyer WJ, Rowinsky EK, Grochow LB, Kaufmann SH, Donehower RC (1994) Camptothecin analogues: studies from the Johns Hopkins Oncology Center. Cancer Chemother Pharmacol [Suppl] 34: S53.
4. Armand JP, Ducreux M, Mahjoubi M, Abigerges D, Bugat R, Chabot G, Herait P, de Forni M, Rougier P (1995) CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 31A: 1283.
5. Takimoto CH, Arbuck SG (1996) The camptothecins. In: Chabner BA, Longo DL (eds) Cancer chemotherapy and biotherapy: principles and practice. 2nd edn. Lippincott - Raven, Philadelphia, p 463
6. Pommier Y (1996) Eukaryotic DNA topoisomerase I: genome gate keeper and its intruders, camptothecins. Semin Oncol 23: 1
7. Chen AY, Liu LF (1994) DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 94: 194
8. Gupta M, Fujimori A, Pommier Y (1995) Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1262: 1
9. O'Connor PM, Kerrigan D, Bertrand R, Kohn KW, Pommier Y (1990) 10,11-methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells. Cancer Commun. 2: 395
10. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y (1994) Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 86: 836
11. Goldwasser F, Bae IS, Torres K, Pommier Y (1995) Topoisomerase I-related parameters and camptothecin activity in the colon cell lines from the National Cancer Institute anticancer screen. Cancer Res 55: 2116
12. Pommier Y, Leteurtre F, Fesen M, Fujimori A, Bertrand R, Solary E, Kohlhagen G, Kohn KW (1994) Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 12: 530
13. Cheng M-F, Chatterjee S, Berger NA (1994) Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res 6: 269
14. Gottesman MM (1993) How cancer cells evade chemotherapy: sixth Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 53: 747
15. Bharti AK, Olson MOJ, Kufe DW, Rubin EH (1996) Identification of a nucleophilin binding site in human topoisomerase I. J Biol Chem 271: 1993
16. Chen AY, Yu C, Potmesil M, Wall ME, Wani MC, Liu LF (1991) Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res 51: 6039
17. Hendricks CB, Rowinsky EK, Grochow LB, Donchower RC, Kaufmann SH (1992) Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268
18. Mattern MR, Hofman GA, Polsky RM, Funk LR, McCabe FL, Johnson RK (1993) In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 5: 467
19. Ambudkar SV, Lelong IH, Zhang J, Cardarelli CO, Gottesman MM, Pastan I (1992) Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA 89: 8472
20. Matsumoto Y, Fujiwara T, Nagao S (1995) Determinants of drug response in camptothecin-11-resistant glioma cell lines. J Neurooncol 23: 1
21. Nagai S, Yamauchi M, Andoh T, Nishizawa M, Satta T, Kodera Y, Kondou K, Akiyama S, Ito K, Takagi H (1995) Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J Surg Oncol 59: 116
22. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol Genet 11: 117
23. Boege F, Straub T, Kehr A, Boesenberg C, Christiansen K, Andersen A, Jakob F, Köhrle J (1996) Selected novel flavones inhibit the DNA binding or the DNA religation step of eukarytotic topoisomerase I. J Biol Chem 271: 2262
24. Cardarelli C, Aksentijevich I, Pastan I, Gottesman MM (1995) Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) and mutant (V185) multidrug transporters. Cancer Res 55: 1086
25. Kohn KW (1991) Principles and practice of DNA filter elution. Pharmacol Ther 49: 55
26. Covey JM, Jaxel C, Kohn KW, Pommier Y (1989) Protein-linked DNA strand breaks induced in mammalian cells by camptothecin, an inhibitor of topoisomerase I. Cancer Res 49: 5016
27. Bertrand R, Pommier Y (1995) Assessment of DNA damage in mammalian cells by DNA filtration methods. In: Studzinski G (ed.) Cell growth and apoptosis: a practical approach, IRL Press, Oxford, p 96
28. Kohn KW, Ewig RAG, Erickson LC, Zwelling LA (1981) Measurement of strand breaks and crosslinks by alkaline elution. In: Friedberg EC, Hanawalt PC (eds) DNA repair: a laboratory manual of research procedures, Marcel Dekker, New York, p 379
29. D'Arpa P, Machlin PS, Ratrie H, Rothfield NF, Cleveland DW, Earnshaw WC (1988) cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci USA 85: 2543
30. Earnshaw WC, Rothfield N (1985) Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma Chromosoma 91: 313
31. Tanizawa A, Bertrand R, Kohlhagen G, Tabuchi A, Jenkins J, Pommier Y (1993) Cloning of Chinese Hamster DNA topoisomerase 1 cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem 268: 25463
32. Taagepera S, Rao PN, Drake FH, Gorbsky GJ (1993) DNA topoisomerase II-alpha is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Proc Natl Acad Sci USA 90: 8407
33. Tanizawa A, Kohn KW, Kohlhagen G, Leteurtre F, Pommier Y (1995) Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry 43: 7200
34. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunki Y, Takemoto Y, Okada K (1987) Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84: 5565
35. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T (1990) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925
36. Woessner RD, Eng W-K, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK (1993) Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res 4: 481
37. Chang J-Y, Dethlefsen LA, Barley LR, Zhou BS, Cheng Y-C (1992) Characterization of camptothecin-resistant chinese hamster lung cells. Biochem Pharmacol 43: 2443
38. Fujimori A, Harker WG, Kohlhagen G, Hoki Y, Pommier Y (1995) Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell resistant to camptothecin. Cancer Res 55: 1339
39. Kanzawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res 50: 5919
40. Tan KB, Mattern MR, Eng W-K, McCabe FL, Johnson RK (1989) Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 81: 1732
41. Fujimori A, Hoki Y, Popescu N and Pommier Y (1996) Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Oncol Res 7/8: 295-301
42. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36: 393
43. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T (1988) Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21: 71
44. Yang C-HJ, Horton JK, Cowan KH, Schneider E (1995) Cross-resistance to camptothecin analogues in mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res 55: 4004
45. Niimi S, Nakagawa K, Sugimoto Y, Nishio K, Fujiwara Y, Yokoyama S, Terashima Y, Saijo N (1992) Mechanism of cross-resistance to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected hy cisplatin. Cancer Res 52: 328
46. Saijo N, Nishio K, Kubota N, Kanzawa F, Shinkai T, Karato A, Sasaki Y, Eguchi K, Tamura T, Ohe Y, et al (1994) 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemother Pharmacol [Suppl] 34: S112
47. Ogasawara H, Nishio K, Kanzawa F, Lee YS, Funayama Y, Ohira T, Kuraishi Y, Isogai Y, Saijo N (1995) Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn J Cancer Res 86: 124
48. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49: 1465